Clinical Significance
Mazdutide represents a significant advancement as the world's first approved dual GLP-1/glucagon receptor agonist. China Phase 3 data (GLORY-1) demonstrates 14.3% average weight loss at 48 weeks with exceptionally low discontinuation rates (0.5%), substantially better tolerability than existing GLP-1 medications.
For patients: While not yet FDA-approved, you can access mazdutide through U.S. Phase 2 clinical trials. China approval data provides robust evidence of efficacy comparable to semaglutide (15.1%) and tirzepatide lower doses, but with dramatically better tolerability. The dual mechanism—combining appetite suppression (GLP-1) with fat burning (glucagon)—offers unique metabolic benefits including 73-80% liver fat reduction.
For clinicians: The DREAMS-3 trial showed mazdutide's superiority vs semaglutide for the combined endpoint (HbA1c <7% + ≥10% weight loss): 48% vs 21%, p<0.0001. This suggests potential advantages for patients requiring both glycemic control and weight management.
What Research Questions Are Being Answered?
The mazdutide clinical trial program investigates dual GLP-1/glucagon agonism across obesity, type 2 diabetes, and metabolic disease
Can mazdutide achieve ≥15% weight loss with better tolerability than existing GLP-1 drugs?
Can mazdutide outperform semaglutide for combined diabetes + weight loss outcomes?
Does glucagon activation provide unique benefits for liver fat reduction beyond GLP-1 alone?
Development History
Mazdutide's path from Phase 1 safety studies to first-in-class approval in China
- 14.3% average weight loss at 48 weeks (4mg and 6mg doses)
- Only 0.5% discontinued due to adverse events (6mg dose)
- 95% of participants achieved ≥5% weight loss
- Approved in China as Xinermei® (June 2025)
First dual GLP-1/glucagon agonist approved globally. Comparable efficacy to semaglutide with dramatically better tolerability profile.
China approval granted June 2025. U.S. Phase 2 trials ongoing with FDA approval estimated 2028-2029.
- BMI ≥28 kg/m² (obesity) or 24-28 kg/m² (overweight with comorbidity)
- Age 18-75 years
- Stable weight for 3 months prior to screening
- HbA1c <6.5% (non-diabetic)
- Type 2 diabetes
- Prior GLP-1 or glucagon agonist use
- History of pancreatitis
- Significant cardiovascular disease
GLORY-1 established mazdutide as the first approved dual GLP-1/glucagon agonist worldwide, demonstrating weight loss comparable to semaglutide with exceptional tolerability (0.5% discontinuation vs 4-7% for comparators). The dual mechanism provides unique liver fat reduction benefits (-73%) unavailable with GLP-1 mono-agonists.
- 48% achieved dual endpoint (HbA1c <7% + ≥10% weight loss)
- vs 21% with semaglutide (2.3-fold superiority)
- Non-inferior glycemic control to semaglutide
- Superior weight loss vs semaglutide
First head-to-head trial showing dual agonist superiority for combined diabetes + weight loss outcomes.
Results support China approval for type 2 diabetes indication (September 2025). U.S. development ongoing.
- Type 2 diabetes with HbA1c 7-10%
- BMI ≥28 kg/m² (obesity)
- On stable diabetes medications
- Type 1 diabetes
- Recent cardiovascular events
- Severe diabetic complications
DREAMS-3 is the first head-to-head trial demonstrating dual GLP-1/glucagon agonist superiority vs GLP-1 mono-agonist for combined diabetes + obesity outcomes. The 2.3-fold higher success rate (48% vs 21%) suggests mazdutide may be preferred for patients requiring both glycemic control and significant weight loss.
Safety & Tolerability
Adverse Events
| Adverse Event | Mazdutide (%) | Placebo (%) | Severity |
|---|---|---|---|
| Nausea | 21–24 | ~6 | Mild-moderate, transient |
| Diarrhea | 29–41 | 8 | Mild-moderate, self-limited |
| Vomiting | 11–16 | ~3 | Mild-moderate, dose titration helps |
| Decreased appetite | 26–31 | 8 | Expected mechanism, mild |
| Constipation | Not specified | Lower | Mild |
| Hypoglycemia (T2D) | 6–16 | Lower | No severe cases (0% blood glucose <54 mg/dL) |
Discontinuation Due to Adverse Events
Access & Trial Participation
Current Trial Status
- China: Approved for obesity (June 2025) and type 2 diabetes (Sept 2025) - Brand name: Xinermei®
- United States: Phase 2 trials recruiting for obesity indication (Eli Lilly)
- U.S. FDA approval: Estimated 2028-2029 (Phase 3 trials not yet announced)
- Additional Phase 3 trials: GLORY-2 (9mg high-dose), GLORY-3 (vs semaglutide in MAFLD), GLORY-OSA (sleep apnea)
U.S. Clinical Trial Enrollment
To check active U.S. clinical trials for mazdutide:
- Visit ClinicalTrials.gov
- Search "mazdutide" OR "IBI362" OR "LY3305677"
- Filter for "Recruiting" or "Not yet recruiting" status
- Check eligibility criteria (typically BMI ≥27-30, no recent GLP-1 use)
- Discuss with your healthcare provider if you meet criteria
- Contact study coordinator listed on ClinicalTrials.gov for screening
Frequently Asked Questions
Not yet. Mazdutide is approved in China (June 2025 for obesity, September 2025 for type 2 diabetes) but currently in Phase 2 trials in the U.S. Eli Lilly holds U.S. rights and is conducting obesity trials. FDA approval is estimated for 2028-2029 after Phase 3 completion.
You can access mazdutide NOW through U.S. Phase 2 clinical trial enrollment. Check ClinicalTrials.gov for active trials.
Efficacy: Mazdutide 6mg achieves 14.3% weight loss, comparable to Wegovy (15.1%) and less than Zepbound 15mg (21%). However, DREAMS-3 showed mazdutide superior to semaglutide for combined diabetes + weight loss endpoint (48% vs 21%).
Tolerability: Mazdutide has dramatically better tolerability with only 0.5% discontinuation vs 4-7% for Wegovy/Zepbound. This is the key differentiator.
Mechanism: Mazdutide is a dual GLP-1/glucagon agonist. The glucagon component provides unique fat burning and liver fat reduction benefits (73-80%) not seen with GLP-1-only drugs.
GLORY-1 reported only 0.5% discontinuation due to adverse events (vs 4-7% for Wegovy/Zepbound and 10-30% for other dual agonists). Phase 2 diabetes trial had 0% AE-related discontinuation through 20 weeks.
Reasons likely include: (1) Optimized dose titration schedule reducing GI side effects, (2) Favorable pharmacokinetic profile with gradual onset, (3) Potential ethnic differences in tolerability (China trials), (4) Careful patient selection in trials.
Real-world data post-approval will clarify if this exceptional tolerability persists across diverse populations.
Dual mechanism of action:
- GLP-1 component: Reduces appetite, slows gastric emptying, improves insulin secretion
- Glucagon component: Increases energy expenditure, enhances fat burning, reduces liver fat
Unique benefits:
- Liver fat reduction: 73-80% (vs ~40% for GLP-1 alone) - critical for MAFLD/NASH
- Energy expenditure: Glucagon activation increases metabolic rate beyond GLP-1 alone
- Comprehensive cardiometabolic benefits: BP, lipids, uric acid, liver enzymes all improved
Current status: Phase 2 trials ongoing in U.S. (Eli Lilly)
Timeline estimates:
- Phase 2 completion: 2025-2026
- Phase 3 trials: Not yet announced (would take 1-2 years)
- NDA submission: Estimated 2027-2028
- FDA approval: Estimated 2028-2029
Access now: Clinical trial enrollment available. China approval data (GLORY-1, DREAMS program) provides strong efficacy/safety evidence supporting future U.S. approval.
Coverage outlook (post-FDA approval):
Likely covered scenarios:
- Type 2 diabetes with obesity (diabetes indication typically covered)
- Severe obesity (BMI ≥35) with comorbidities
- Patients who failed or cannot tolerate semaglutide/tirzepatide
Uncertain coverage:
- Obesity alone (BMI 30-34.9) without comorbidities - varies by plan
- Cosmetic weight loss - unlikely
Key factor: Mazdutide's exceptional tolerability (0.5% discontinuation) may support coverage as alternative for patients intolerant to Wegovy/Zepbound. Prior authorization will likely be required.
References
- [1]Ji L, Jiang H, Bi Y, et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med. 2025;392(22):2215-2225. doi:10.1056/NEJMoa2411528View source →
- [2]Jia W, Weng J, Zhu D, et al. Safety and efficacy of the GLP-1/glucagon receptor co-agonist mazdutide (IBI362) in Chinese patients with overweight or obesity: A randomized, placebo-controlled, phase 2 trial. Nat Commun. 2023;14:8411. doi:10.1038/s41467-023-44067-4View source →
- [3]Innovent Biologics. DREAMS-3 trial results presented at EASD 2024. Mazdutide vs semaglutide in type 2 diabetes with obesity. September 2024.View source →
- [4]Zhao X, Wang M, Wen J, et al. GLP-1 receptor agonists: beyond their pancreatic effects. Front Endocrinol. 2024;14:1225292.View source →
- [5]ClinicalTrials.gov. A Study of IBI362 (LY3305677) in Participants With Obesity or Overweight (GLORY-1). NCT05607680. Updated 2025.View source →
- [6]ClinicalTrials.gov. A Study to Learn How Well Mazdutide Works and How Safe it is in Chinese Adults With Obesity (GLORY-2). NCT06164873. Updated 2025.View source →
- [7]ClinicalTrials.gov. A Study to Learn if Mazdutide Works Better Than Semaglutide in Adults With BMI≥27 kg/m2 and MAFLD (GLORY-3). NCT06884293. Updated 2025.View source →
- [8]China National Medical Products Administration (NMPA). Approval of Xinermei® (mazdutide) for chronic weight management in adults with obesity. June 2025.View source →
- [9]Eli Lilly. Mazdutide development timeline and U.S. clinical trial program. Corporate press releases 2024-2025.View source →
- [10]Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102.View source →
Last updated October 6, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.